Filtered By:
Therapy: Neoadjuvant Chemotherapy Therapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 26 results found since Jan 2013.

Cancers, Vol. 14, Pages 3726: Identification of Src as a Therapeutic Target in Oesophageal Adenocarcinoma through Functional Genomic and High-Throughput Drug Screening Approaches
In conclusion, a compound screen together with a functional genomic approach identified Src as a potential chemosensitising target in OAC, which could be assessed in a clinical study for poor prognosis OAC patients.
Source: Cancers - July 30, 2022 Category: Cancer & Oncology Authors: Niamh H. McCabe Leanne Stevenson Enya Scanlon Rosalie Douglas Susanna Kennedy Oliver Keminer Bj örn Windshügel Daniela Zisterer Richard D. Kennedy Jaine K. Blayney Richard C. Turkington Tags: Article Source Type: research

NRF2 Mediates Therapeutic Resistance to Chemoradiation in Colorectal Cancer through a Metabolic Switch
Antioxidants (Basel). 2021 Aug 28;10(9):1380. doi: 10.3390/antiox10091380.ABSTRACTRadiation resistance is a significant clinical problem in rectal cancer treatment, the mechanisms of which are poorly understood. NRF2 signalling is known to contribute to chemo/radioresistance in some cancers, but its role in therapeutic resistance in colorectal cancer (CRC) is unexplored. Using siRNA and CRiSPR/Cas9 isogenic CRC cell lines, we investigated the effect of the knockdown and upregulation of the NRF2 pathway on chemo-radiosensitivity. Poly (A) enriched RNA sequencing and geneset enrichment analysis (GSEA) were carried out on bot...
Source: Cell Research - September 28, 2021 Category: Cytology Authors: S éan M O'Cathail Chieh-Hsi Wu Rachael Thomas Maria A Hawkins Tim S Maughan Annabelle Lewis Source Type: research

Cancers, Vol. 13, Pages 3903: Identification of CNGB1 as a Predictor of Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
Rakesh Heer Cisplatin-based neoadjuvant chemotherapy (NAC) is recommended prior to radical cystectomy for muscle-invasive bladder cancer (MIBC) patients. Despite a 5–10% survival benefit, some patients do not respond and experience substantial toxicity and delay in surgery. To date, there are no clinically approved biomarkers predictive of response to NAC and their identification is urgently required for more precise delivery of care. To address this issue, a multi-methods analysis approach of machine learning and differential gene expression analysis was undertaken on a cohort of 30 MIBC cases highly selected for an...
Source: Cancers - August 2, 2021 Category: Cancer & Oncology Authors: Anastasia C. Hepburn Nicola Lazzarini Rajan Veeratterapillay Laura Wilson Jaume Bacardit Rakesh Heer Tags: Article Source Type: research

Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma
CONCLUSIONS: The present study confirms over-expression of CA9 in UC and for the first time shows a correlation with molecular subtypes. However, CA9 expression showed no association with the outcome of patients with muscle invasive bladder cancer and inhibition of CA9 did not lead to a consistent inhibition of tumor growth. Based on these data, CA9 exhibits a role neither as a predictive or prognostic marker nor as a therapeutic target in invasive UC.PMID:34083096 | DOI:10.1016/j.urolonc.2021.04.011
Source: Urologic Oncology - June 4, 2021 Category: Urology & Nephrology Authors: Tilman Todenh öfer Ewan A Gibb Roland Seiler Alireza Kamyabi J örg Hennenlotter Paul McDonald Igor Moskalev Craig Stewart Jian Gao Ladan Fazli Shoukat Dedhar Arnulf Stenzl Htoo Zarni Oo Peter C Black Source Type: research

Down-regulation of FOS-like antigen 1 enhances drug sensitivity in breast cancer.
CONCLUSION: Down-regulation of FOSL1 potentiated chemotherapy sensitivity of breast cancer, and its lower expression attenuated chemotherapeutic drug resistance in human breast cancer cells. FOSL1 might be a drug target for predicting chemotherapy effect in breast cancer. PMID: 32922605 [PubMed]
Source: International Journal of Clinical and Experimental Pathology - September 15, 2020 Category: Pathology Authors: Duan L, Zhao M, Ang L, Hu H, Wu Z, Wang J, Huang J, Zheng L, Dong W Tags: Int J Clin Exp Pathol Source Type: research

298PTargeting CDCA3 to improve chemotherapy response in triple negative breast cancer patients
ConclusionsOur data highlight CDCA3 as a novel prognostic factor in TNBC that modulates sensitivity to chemotherapy. These findings point to the therapeutic potential of targeting CDCA3 in TNBC.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research

Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin.
CONCLUSION: Our study suggested that Nek2B can bind to β-catenin and the co-expression correlated with TNBC patients poor prognosis. It appears that Nek2B and β-catenin might synergize to promote chemotherapy resistance. PMID: 31174562 [PubMed - in process]
Source: Clinical Genitourinary Cancer - June 6, 2019 Category: Cancer & Oncology Authors: Shen H, Yan W, Yuan J, Wang Z, Wang C Tags: J Exp Clin Cancer Res Source Type: research

Relationship between microRNA-27a and efficacy of neoadjuvant chemotherapy in gastric cancer and  mechanism in gastric cancer cell growth and metastasis.
CONCLUSION: Collectively, our study highlights that the high expression of miR-27a indicates the poor efficacy and prognosis of neoadjuvant chemotherapy in GC patients. Down-regulation of miR-27a can inhibit the growth and metastasis of GC cells via up-regulation of SFRP1. PMID: 30902884 [PubMed - as supplied by publisher]
Source: Bioscience Reports - March 21, 2019 Category: Biomedical Science Authors: Xu C, Cheng H, Li N, Zhou N, Tang X Tags: Biosci Rep Source Type: research

Pretreatment TACC3 expression in locally advanced rectal cancer decreases the response to neoadjuvant chemoradiotherapy.
In this study, we investigated whether TACC3 could serve as a biomarker predictive of the efficacy of chemoradiotherapy. In all, 152 rectal cancer patients with tumor tissue collected at biopsy and set aside before treatment were enrolled in this study. All patients received chemoradiotherapy and surgical resection. Immunohistochemically detected tumoral TACC3 expression significantly decreased sensitivity to chemoradiotherapy [risk ratio (RR) = 2.236, 95% confidence interval (CI): 1.447-3.456; P = 0.001] and thus the pathological complete response rate (P = 0.001). TACC3 knockdown using specific siRNA enhanced radiotherap...
Source: Aging - October 19, 2018 Category: Biomedical Science Authors: Ma WJ, Gu YK, Peng JH, Wang XC, Yue X, Pan ZZ, Chen G, Xu HN, Zhou ZG, Zhang RX Tags: Aging (Albany NY) Source Type: research

The action mechanism of lncRNA-HOTAIR on the drug resistance of non-small cell lung cancer by regulating Wnt signaling pathway.
Authors: Guo F, Cao Z, Guo H, Li S Abstract The action mechanism of long non-coding ribonucleic acid-homeobox transcript antisense ribonucleic acid (lncRNA-HOTAIR) in the regulation of the Wnt signaling pathway on the drug resistance of non-small cell lung cancer was investigated. Forty eight patients with non-small cell lung cancer, who were treated with cisplatin (DDP) as neoadjuvant chemotherapy, were selected from the specimen bank of the Department of Pathology of Peking Union Medical College Hospital. Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect the messenger RNA (mRNA) level of...
Source: Experimental and Therapeutic Medicine - May 30, 2018 Category: General Medicine Tags: Exp Ther Med Source Type: research

Interferon beta induces apoptosis in nasopharyngeal carcinoma cells via the TRAIL-signaling pathway.
In conclusion, IFNβ leads to apoptosis in NPC cells in an autocrine way via the induction of TRAIL expression and subsequent activation of the TRAIL-signaling pathway. The mechanism described could at least partly explain the clinical benefit of IFNβ in the treatment of NPC. Further studies in a mouse-xenograft model are warranted to substantiate this effect in vivo. PMID: 29581840 [PubMed]
Source: Oncotarget - March 29, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Capecitabine efficacy is correlated with TYMP and RB expression in PDX established from triple-negative breast cancers.
CONCLUSIONS: we identified capecitabine as efficient chemotherapy in TNBC PDX models established from residual disease and resistant to anthracyclines, taxanes and platins. RB positivity and high expression of TYMP were significantly associated with capecitabine response. PMID: 29463559 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - February 20, 2018 Category: Cancer & Oncology Authors: Marangoni E, Laurent C, Coussy F, El Botty R, Chateau-Joubert S, Servely JL, de Plater L, Assayag F, Dahmani A, Montaudon E, Némati F, Fleury J, Vacher S, Gentien D, Rapinat A, Foidart P, Sounni NE, Noël A, Salomon A, Lae M, Decaudin D, Roman-Roman S, B Tags: Clin Cancer Res Source Type: research

Abstract B08: ER chaperone GRP78 increases chemoresistance in pancreatic ductal adenocarcinoma
Conclusions: Collectively, our data show that GRP78 expression promotes chemoresistance in PDAC and therapeutic strategies blocking the activity of GRP78 increase the efficacy of currently available therapies.Citation Format: Jenifer B. Gifford, Wei Huang, Ann E. Zeleniak, Antreas Hindoyan, Hong Wu, Timothy R. Donahue, Reginald Hill.{Authors}. ER chaperone GRP78 increases chemoresistance in pancreatic ductal adenocarcinoma. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2016 May 12-15; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2016;76(24 Suppl):Abstract nr B08.
Source: Cancer Research - December 13, 2016 Category: Cancer & Oncology Authors: Jenifer B. Gifford, Wei Huang, Ann E. Zeleniak, Antreas Hindoyan, Hong Wu, Timothy R. Donahue, Reginald Hill Tags: Molecular Drivers of Pancreatic Cancer Biology and Metastasis Source Type: research